



BGDO Session Program

Scientific Group: BGDO

Day: Friday, February 14, 2025

08:00-08:30 Satellite Symposium BMS

Session 1

Moderators : Timon Vandamme, UZA, Antwerpen and Veerle Casneuf, OLV Aalst (Azorg), Aalst

- 08:30 57 **O01 Prevalence of claudin 18.2 positivity in a Belgian cohort of patients with gastroesophageal cancer.**
 F. VAN HERPE (1), F. DEMAN (2), G. RASSCHAERT (1), M. DE WIT (1), K. DUMON (1), R. GOVAERTS (1), S. ROMANUS (1), S. CAPPUYNS (1), J. DEKERVEL (1) / [1] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Gastroenterology - GI Oncology, [2] Ziekenhuis aan de Stroom Antwerpen, Antwerpen, Belgium, Pathology
- 08:40 201 **O02 Perioperative FLOT Chemotherapy for Locally Advanced Oesophageal Adenocarcinoma: From ESOPEC To Daily Practice.**
 A. BOUCKAERT (1), F. VAN HERPE (2), J. MOONS (1), S. VANSTRAELEN (1), J. DEKERVEL (2), L. DEYPERE (1), K. HAUSTERMANS (3), T. LERUT (1), Y. MANDEVILLE (4), H. VAN VEER (1), P. NAFTEUX (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Thoracic Surgery, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and Digestive Oncology, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Radiation Oncology, [4] AZ Delta, Belgium, General, Abdominal and Thoracic Surgery
- 08:50 43 **O03 The prognostic value of circulating tumor DNA in curatively treated gastroesophageal cancer treated: a systematic review and meta-analysis.**
 F. VAN HERPE (1), Q. VAN CAENEGEM (2), G. RASSCHAERT (1), S. CAPPUYNS (3), J. DEKERVEL (1) / [1] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Gastroenterology - GI Oncology, [2] University Hospitals Gasthuisberg, Leuven and KU Leuven,

Leuven, Belgium, Gastro-enterology, [3] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Gastro-enterology - GI oncology

09:00 Discussant abstracts O01-O03 on esogastric cancer:
E Callebout, UZ Ghent, Ghent

09:20 83 O04 **Results of the EORTC survey on the management of non-metastatic pancreatic adenocarcinoma: a focus on radiotherapy.**
C. BOUCHART (1), M. DELAYE (2), I. GARAJOVA (3), F. HUGUET (4), C. NEUZILLET (2) / [1] Institut Jules Bordet, Brussels, Belgium, Radiotherapy-Oncology, [2] Institut Curie, Saint Cloud, France, Medical Oncology, [3] University Hospital of Parma, Parma, Italy, Medical Oncology Unit, [4] Hopital Tenon, Paris, France, Radiation Oncology

09:30 **Invited Lecture:** Radiotherapy in pancreatic cancer.
Genevieve Van Ooteghem, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium

10:00 – 10:30 Coffee Break

Session 2

Moderators: Ivan Borbath, Cliniques Universitaires Saint-Luc, Bruxelles and Karen Geboes, UZ Ghent, Gent

10:30 183 O05 **Efficacy and safety of chemoembolization in very early and early Stage hepatocellular carcinoma.**
DE BUCK VAN OVERSTRAETEN (1), M. PEZZULLO (2), A. BUCALAU (1), M. VAN WETTERE (2), I.TANCREDI (3), F. TANNOURY (2), A. DEMOLS (1), G. VERSET (4) / [1] HUB Hôpital Erasme, Brussels, Belgium, Gastroenterology, [2] HUB Hôpital Erasme, Brussels, Belgium, Radiology, [3] CHU de Charleroi, Hôpital Marie Curie, Charleroi, Belgium, Radiology, [4] Erasme Hospital, Brussels, Belgium, Gastroenterology

10:40 232 O06 **Analysis of the effectiveness of the combination of Atezolizumab and Bevacizumab as first-line treatment for advanced hepatocellular carcinoma. A real-world retrospective multicenter study in Belgium.**
S. HAXHE (1), A. VAN THILLO (2), F. PEETERS (2), A. COLLARD (3), G. VERSET (4), H. VAN VLIERBERGHE (5), G. HOUBIERS (6), T. VANDAMME (7), J. CARRASCO (8), J. DEKERVEL (2), I. BORBATH (1) / [1] UCLouvain, Cliniques Universitaires St Luc, Belgium, Hepato-Gastroenterology, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Digestive oncology, [3] UCLouvain, Cliniques Universitaires St Luc, , Belgium, Statistics, [4] Erasme University Hospital - Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Hepato-Gastroenterology, [5] Universitair ziekenhuis Gent, , Belgium, Hepato-Gastroenterology, [6] Clinique Mont Legia - CHC Groupe Santé, Liège, Belgium, Hepato-Gastroenterology, [7] UZA, Universitair Ziekenhuis Antwerpen, Edegem,

Belgium, Oncology, [8] Grand Hopital de Charleroi, Charleroi, Belgium, Oncology

10:50 – 11:05: Discussant abstracts O05-O06 on HCC
Koen Kortbeek (UZ Brussel)

11:05 101 **O07 NET-IMPRESS: a Novel Methylation-based Assay to Diagnose and Monitor NET patients using Liquid Biopsies.**
L. MARIËN (1), J. IBRAHIM (2), N. DE MEULENAERE (2), S. CHHAJLANI (2), I. NEEFS (2), J. VANDENHOECK (2), T. VANPOUCKE (2), W. LYBAERT (3), M. PEETERS (4), G. VAN CAMP (2), K. OP DE BEECK (5), T. VANDAMME (6) / [1] University of Antwerp, Antwerp, Belgium, Center for Medical Genetics, [2] University of Antwerp, Antwerp, Belgium, Center for Medical Genetics, [3] NETwerk, VITAZ/UZA, Edegem, Belgium, Department of Medical Oncology, [4] University of Antwerp/Antwerp University Hospital, Edegem, Belgium, Center for Oncological Research, [5] University of Antwerp, Antwerp, Belgium, Center for Medical Genetics and Center for Oncological Research, [6] University of Antwerp/Antwerp University Hospital, Edegem, Belgium, Center for Oncological Research and Department of Oncology

11:15 61 **O08 A novel immune-based score and its immune contexture exploration in colorectal cancer.**
Q. WU (1), A. PEDDLE (1), S. RUSAKIEWICZ (2), K. YIN (1), Z. HU (1), F. VAN HERPE (3), A. D'HOORE (4), Y. HONG (1), S. VERBANDT (1), S. TEJPAR (3), G. RASSCHAERT (3) / [1] KUL – University of Leuven, Leuven, Belgium, Laboratory for Digestive Oncology, [2] Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, Immune Landscape Laboratory, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Abdominal Surgery

11:25-11:40: Discussant abstracts O05-6 on markers:
F Sciafani, HUB, Brussels

11:40 **Invited Lecture:** Causes of early onset digestive cancers.
Alice Boileve, Cheffe de Clinique d'Oncologie Digestive, Gustave Roussy, Paris, France

12:20 BGDO award and conclusions

12:30-13:00 Satellite Symposium KENVUE

e-POSTERS:

186 O09 Is intensive ischemia-reperfusion injury increasing the risk of hepatocellular carcinoma recurrence after liver transplantation?
M. FOGUENNE (1), O. CICCARELLI (2), L. COUBEAU (2), G. DAHLQVIST (3),

E. BONACCORSI RIANI (2) / [1] Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium, Abdominal Surgery and Transplantation, [2] Cliniques universitaires Saint-Luc, Brussels, Belgium, Abdominal Surgery and Transplantation, [3] Cliniques universitaires Saint-Luc, Brussels, Belgium, Hepato-Gastro-Enterology

- 162 O10 Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio to predict response to gemcitabine-cisplatin-durvalumab in unresectable cholangiocarcinoma: an international, multicenter, retrospective cohort study.
- H. VANDEPUTTE (1), F. PEETERS (2), A. CASADEIGARDINI (3), M. RIMINI (3), L. FORNARO (4), M. RIZZATO (5), L. ANTONUZZO (6), F. ROSSARI (3), S. TOMOYUKI (7), C. VIVALDI (4), T. PRESSIANI (8), J. LUCCHETTI (9), J. WON KIM (10), A. OLUSEYI (11), I. GIOVANNI RAPPOSELLI (12), S. TAMBERI (13), F. FINKELMEIER (14), G. GIORDANO (15), F. NICHETTI (16), H. JAE CHON (17), C. BRACONI (18), C. PIRRONE (19), F. CASTET (20), E. TAMBURINI (21), C. YOO (22), A. PARISI (23), A. DIANA (24), M. SCARTOZZI (25), G. PRAGER (26), A. AVALLONE (27), M. SCHIRRIPA (28), I. HWAN KIM (29), L. PERKHOFER (30), E. ONEDA (31), M. VERRICO (32), J. ADEVA (33), S. L CHAN (34), G. SPINELLI (32), N. PERSONENI (35), I. GARAJOVA (36), M. RODRIQUENZ (37), S. LEO (38), F. SALANI (39), A. DE ROSA (40), D. LAVACCHI (6), S. FOTI (3), M. IKEDA (7), M. NIGER (16), R. BALSANO (8), G. TONINI (39), M. KANG (10), T. BEKAI-SAAB (11), L. ESPOSITO (12), A. BOCCACCINO (13), V. HIMMELSBACH (14), M. LANDRISCINA (15), S. AHCENE DJABALLAH (40), V. ZANUSO (8), G. MASI (4), S. LONARDI (40), L. RIMASSA (8), J. DEKERVEL (2) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Algemene basisopleiding, [2] KUL - University of Leuven, Leuven, Belgium, digestive oncology, [3] Vita Salute San Raffaele University, Milan , Italy, digestive oncology, [4] Azienda Ospedaliero-Universitaria Pisana, pisa, Italy, digestive oncology, [5] Veneto Institute of Oncology IOV, padua, Italy, digestive oncology, [6] Careggi University Hospital, florence, Italy, digestive oncology, [7] National Cancer Center Hospital East, kashiwa, Japan, digestive oncology, [8] IRCCS Humanitas Research Hospital, milan, Italy, digestive oncology, [9] Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, Rome, Italy, digestive oncology, [10] Seoul National University Bundang Hospital, seoul, Korea (the Republic of), digestive oncology, [11] Mayo Clinic, Phoenix, United States (the), digestive oncology, [12] IRCCS Istituto Romagnolo per Lo Studio Dei Tumori, Meldola, Italy, digestive oncology, [13] Santa Maria delle Croci hospital, Ravenna, Italy, digestive oncology, [14] University Hospital Goethe-University, frankfurt, Germany, digestive oncology, [15] Policlinico Riuniti, Foggia, Italy, digestive oncology, [16] Fondazione IRCC Istituto Nazionale dei Tumori, milan, Italy, digestive oncology, [17] CHA Bundang Medical Center, Seongnam, Korea (the Republic of), digestive oncology, [18] University of Glasgow, Beatson West of Schotland Cancer Centre, Glasgow, United Kingdom (the), digestive oncology, [19] IRCC Ospedale Policlinico San Martino, Genova, Italy, digestive oncology, [20] Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca, Barcelona, Spain,

digestive oncology, [21] Cardinale Panico Tricase City Hospital, Tricase, Italy, digestive oncology, [22] ASAN Medical Center, University of Ulsan College of Medicine, Ulsan, Korea (the Republic of), digestive oncology, [23] Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy, digestive oncology, [24] Ospedale del Mare, Napoli, Italy, digestive oncology, [25] University of Cagliari, Cagliari, Italy, digestive oncology, [26] Medical University of Vienna, Vienna, Austria, austria, [27] Istituto Nazionale Tumori-IRCCS Fondazione G Pascale, Napoli, Italy, digestive oncology, [28] Belcolle hospital, Viterbo, Italy, digestive oncology, [29] Haeundae Paik Hospital, Busan, Korea (the Republic of), digestive oncology, [30] Institute of Molecular Oncology and Stem Cell biology, Ulm, Germany, digestive oncology, [31] Fondazione Poliambulanza, Brescia, Italy, digestive oncology, [32] Sapienza University of Rome, Rome, Italy, digestive oncology, [33] Spanish Society of Medical Oncology, Madrid, Spain, digestive oncology, [34] The Chinese University of Hong Kong, Hong Kong, China, digestive oncology, [35] ASST Garda, Brescia, Italy, digestive oncology, [36] University Hospital of Parma, Parma, Italy, digestive oncology, [37] Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy, digestive oncology, [38] Vito Fazzi Hospital, Lecce, Italy, digestive oncology, [39] Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy, digestive oncology, [40] IRCCS Padua, padua, Italy, digestive Oncology

- 163 O11 STATUS AND ROLE OF HELICOBACTER PYLORI INFECTION IN IMMUNOTHERAPY RESPONSE IN OESOGASTRIC ADENOCARCINOMA. E. LAM (1), L. VERSET (2), A. NEBBIOSO (3), A. BUCALAU (1), J. VAN LAETHEM (1) / [1] Hopitaux Universitaires de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Belgium, Gastro-enterology and digestive oncology, [2] Hopitaux Universitaires de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Belgium, Pathology, [3] Hôpitaux Iris Sud, Brussels, Belgium, Pediatrics
- 104 O12 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – a systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence. S. CHHAJLANI (1), C. LAMBRECHTS (2), O. ISLAM (1), C. DE WEERDT (1), L. MARIËN (3), L. VERBRUGGEN (1), M. SIMOENS (4), M. ULENAERS (5), D. GALDERMANS (6), W. DEMEY (7), I. VAN DER MASSEN (1), W. LYBAERT (8), T. VANDAMME (1) / [1] UZA - NETwerk, Edegem, Belgium, Medical Oncology, [2] AZ Heilig Hart ziekenhuis Mol, Mol, Belgium, Gastro-enterology, [3] Universiteit Antwerpen - NETwerk, Antwerp, Belgium, Medical Genetics, [4] ZAS - NETwerk, Antwerp, Belgium, Gastro-enterology, [5] AZ Rivierenland – NETwerk, Bornem, Belgium, Gastro-enterology, [6] ZAS - NETwerk, Antwerp, Belgium, Respiratory medicine, [7] AZ Klina - NETwerk, Brasschaat, Belgium, Medical Oncology, [8] VITAZ - NETwerk, Sint-Niklaas, Belgium, Medical Oncology
- 130 O13 Clinical Utility of [¹⁸F]AIF-NOTA-Octreotide for Somatostatin Receptor PET/CT:

A Retrospective Study in 288 Patients with Neuroendocrine Neoplasms.
H. LEUPE (1), J. DEKERVEL (2), F. CLEEREN (3), K. GOFFIN (4), C. DOOMS (5),
S. JENTJENS (4), L. BOECKXSTAENS (4), E. VAN CUTSEM (2), F. VAN HERPE (2),
P. CLEMENT (6), G. RASSCHAERT (2), K. VAN LAERE (4), G. BORMANS (3),
C. VERSLYPE (2), C. DEROOSE (4) / [1] University Hospitals Leuven (UZLeuven),
Leuven, Belgium, Nucleaire geneeskunde, [2] University Hospitals Leuven
(UZLeuven), Leuven, Belgium, Digestive Oncology, [3] KUL - University of
Leuven, Leuven, Belgium, Radiopharmaceutical Research, [4] University
Hospitals Leuven (UZLeuven), Leuven, Belgium, Nuclear Medicine,
5] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of
Respiratory Diseases, [6] University Hospitals Leuven (UZLeuven), Leuven,
Belgium, Oncology

- 148 O14 Analysis of the Clinical, Biological, and Prognostic Features of Patients with
Colorectal Cancer Exhibiting Multiple RAS Gene Mutations.
R. DI GIUGNO (1), M. MEYERS (2), F. SCLAFANI (2) / [1] CUB Hôpital Erasme,
Belgium, Gastroenterology, [2] Institut Jules Bordet, Brussels, Belgium,
Oncology
- 1 O15 The Relationship Between Pretherapeutic Malnutrition According To GLIM
Criteria And Clinical Outcomes In Patients With Colorectal Cancer.
S. ZAUGA (1), S. BEN HAMIDA (1), H. ELLOUMI (1), I. CHEIKH (1) / [1] Habib
Bougatfa Hospital, Tunisia, Gastroenterology